Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 6/20 | 0.65 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.65 |
| ▸ | BRAF | P15056 | 11/20 | 0.55 |
| ▸ | KIT | P10721 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21046877 | 0.91 | MAP2K4 (0.58) | MAP2K4MAP2K7BRAF | |
| SCHEMBL21046930 | 0.91 | MAP2K4 (0.57) | MAP2K4MAP2K7BRAFKIT | |
| SCHEMBL21046991 | 0.87 | BRAF (0.59) | MAP2K4MAP2K7BRAF | |
| SCHEMBL21046769 | 0.85 | BRAF (0.77) | BRAF | |
| SCHEMBL22819386 | 0.79 | MAP2K4 (1.00) | MAP2K4MAP2K7 | |
| SCHEMBL22374557 | 0.76 | BRAF (0.74) | BRAFKIT | |
| SCHEMBL21046814 | 0.75 | BRAF (0.73) | BRAFKIT | |
| SCHEMBL19872439 | 0.73 | MAP2K7 (0.42) | MAP2K4MAP2K7BRAF | |
| SCHEMBL21047291 | 0.71 | BRAF (0.68) | BRAFKIT | |
| SCHEMBL1461049 | 0.70 | MAP2K4 (0.67) | MAP2K4MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498693-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-3498693-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696651-B2 | Heterocyclic compound | EIF2AK4, GCN1, GTF2I | MAP2K4 3637/4885MAP2K7 2747/4885BRAF 1618/4885 |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | EIF2AK4, GCN1, GTF2I | MAP2K4 3637/4885MAP2K7 2747/4885BRAF 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.